论文部分内容阅读
目的:评价同胞供者异基因外周血干细胞移植(allo-PBSCT)治疗骨髓增生异常综合征(MDS)患者的疗效。方法:1998年5月-2007年4月对18例MDS及MDS转急性髓系白血病(AML)患者进行同胞供者al-lo-PBSCT治疗。其中供受者HLA A、B、DR 6个位点相合者16例,5个位点相合者2例。预处理主要采用修改的Bu-Cy方案。结果:所有患者移植后均重建造血,中性粒细胞数>0.5×109/L中位时间为移植后15.5(11~28)d,血小板≥20×109/L中位时间为移植后17(10~50)d。移植后3年总生存率(OS)及无病生存率(DFS)均为(43.2±12.0)%,3年复发率(RR)(9.2±7.0)%,移植相关死亡率(TRM)(42.1±12.0)%,移植后继发肿瘤2例。截止随访日期,存活10例,中位生存时间16.5(2~112)个月。结论:同胞供者allo-PBSCT是治疗MDS的有效方法。
Objective: To evaluate the efficacy of sibling donor allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in the treatment of patients with myelodysplastic syndrome (MDS). METHODS: From May 1998 to April 2007, 18 patients with MDS and MDS-AML were treated with sibling donor al-lo-PBSCT. Among them, there were 16 matched patients with HLA A, B and DR, and 2 patients with 5 matched sites. Pretreatment mainly uses the modified Bu-Cy scheme. Results: The hematopoiesis was reconstructed in all the patients. The median time of neutrophil count> 0.5 × 109 / L was 15.5 (11-28) days after transplantation, and the median time of platelet ≥20 × 109 / L was 17 ( 10 ~ 50) d. The 3-year OS and DFS were (43.2 ± 12.0)%, 3-year recurrence (RR) (9.2 ± 7.0)%, and transplant-related mortality (TRM) ± 12.0)%, secondary tumor after transplantation in 2 cases. As of the follow-up date, 10 patients survived, with a median survival time of 16.5 (ranged from 2 to 112) months. Conclusion: Allo-PBSCT is an effective method to treat MDS.